Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Other Non-Current Liabilities (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $80.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 20.24% to $80.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.2 million through Dec 2025, up 20.24% year-over-year, with the annual reading at $80.2 million for FY2025, 20.24% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $80.2 million at BeOne Medicines, up from $64.1 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $180.5 million in Q4 2022, with the low at $42.0 million in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $60.9 million, with a median of $53.0 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities soared 232.77% in 2022, then tumbled 71.85% in 2023.
  • Over 5 years, Other Non-Current Liabilities stood at $54.2 million in 2021, then skyrocketed by 232.77% to $180.5 million in 2022, then crashed by 71.85% to $50.8 million in 2023, then soared by 31.34% to $66.7 million in 2024, then grew by 20.24% to $80.2 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $80.2 million, $64.1 million, and $63.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.